Recruiting MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib NCT07463651 Conditions Acute Myeloid Leukemia (AML), Allogeneic Hematopoietic Cell Transplantation (HCT), FLT3-ITD Mutation, +10 more Locations the First Affiliated Hosptital of Soochow University — Suzhou, Jiangsu, China Ruijin Hospital, Shanghai Jiaotong University School of Medicine — Shanghai, Shanghai Municipality, China View Trial Details
Recruiting A Clinical Study of Sorafenib Combined With Gefitinib for the Treatment of pNET NCT06592989 Conditions Adenoma, Adenoma, Islet Cell, Digestive System Diseases, +12 more Locations Shanghai General Hospital — Shanghai, Shanghai Municipality, China View Trial Details
Completed TACE, Sorafenib and PD-1 Monoclonal Antibody in the Treatment of HCC NCT04518852 Conditions Adenocarcinoma, Antineoplastic Agents, Carcinoma, +13 more Locations Sichuan Cancer Hospital and Research Institute — Chengdu, Sichuan, China View Trial Details
Completed TACE Plus Sorafenib Versus TACE Alone for Recurrent Intermediate Hepatocellular Carcinoma NCT04103398 Conditions Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +11 more Locations The First Affiliated Hospital of Sun Yat-sen University — Guangzhou, Guangdong, China View Trial Details
Completed Palliative Treatments for Patients With Advanced Hepatocellular Carcinoma (HCC) NCT01409499 Conditions Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +11 more Locations Sun Yat-sen University Cancer Center — Guangzhou, Guangdong, China View Trial Details
